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SUMMARY
In vitro modeling of human disease has recently
become feasible with induced pluripotent stem cell
(iPSC) technology. Here, we established patient-
derived iPSCs from a Li-Fraumeni syndrome (LFS)
family and investigated the role of mutant p53 in
the development of osteosarcoma (OS). LFS iPSC-
derived osteoblasts (OBs) recapitulated OS features
including defective osteoblastic differentiation as
well as tumorigenic ability. Systematic analyses re-
vealed that the expression of genes enriched in
LFS-derived OBs strongly correlated with decreased
time to tumor recurrence and poor patient survival.
Furthermore, LFS OBs exhibited impaired upregula-
tion of the imprinted gene H19 during osteogenesis.
Restoration of H19 expression in LFS OBs facilitated
osteoblastic differentiation and repressed tumori-
genic potential. By integrating human imprinted
gene network (IGN) into functional genomic ana-
lyses, we found that H19 mediates suppression of
LFS-associated OS through the IGN component
DECORIN (DCN). In summary, these findings demon-
strate the feasibility of studying inherited human can-
cer syndromes with iPSCs.
INTRODUCTION
Li-Fraumeni syndrome (LFS) is a genetically heterogeneous
inherited cancer syndrome characterized by autosomal domi-
nance and early onset of often multiple independent tumors
within affected family members (Li and Fraumeni, 1969). In
contrast to other inherited cancer syndromes predominantly
characterized by site-specific cancers, LFS patients present
with a variety of tumor types, including osteosarcoma (OS),
soft tissue sarcoma, breast cancer, brain tumor, leukemia,
and adrenocortical carcinoma. Germline mutations in the TP53
gene encoding the tumor suppressor p53 are responsible for
LFS (Malkin et al., 1990). Mutations in p53 usually not only
abolish normal p53 function but are also associated with addi-
tional oncogenic activities. Despite the prevalence of p53 muta-
tions, the simultaneous presence of alterations in other tumor
suppressors (e.g., RB1 and LKB1) and oncogenes (KRAS and
HER2) makes it extremely difficult to study the specific role of
p53 in cancer development. LFS provides an ideal genetic model
system for investigating such a role. Although murine LFS
models have been generated (Hanel et al., 2013; Lang et al.,
2004; Olive et al., 2004), they do not fully recapitulate the tumor
spectrum found in LFS patients. Therefore, other model systems
are needed in order to further decipher mutant p53-associated
pathogenesis.
Comprising almost 60% of the common histological bone sar-
coma subtypes, OS is the most frequent primary non-hemato-
logical malignancy in childhood and adolescence (Tang et al.,
2008). Despite advances in surgery and multi-agent chemo-
therapy, the survival rate has not increased in the past 40 years
as much as for other malignancies. After leukemia, OS is the
second leading cause of cancer mortality among children and
adolescents and has been described as a cancer syndrome
with a differentiation deficiency. OS exhibits osteoblast (OB)-
like features and sustains undifferentiated OBs (Haydon et al.,
2007). Furthermore, genetic alterations (e.g., p53 mutation and
RB deletion) are strongly associated with OS development.
Although the association of TP53 mutation with OS is strongly
supported by the high risk of OS in LFS patients (Porter et al.,
1992), the underlying mechanism by which triggers OS develop-
ment is still unclear.
H19 is a maternally imprinted gene encoding a long non-cod-
ing RNA (lncRNA). Alterations in the expression of genes in the
H19-IGF2 imprint locus are linked to both Beckwith-Wiedemann
syndrome (BWS) and Russell-Silver syndrome (RSS) (Choufani
et al., 2010; Eggermann, 2010). Gain of methylation of the up-
stream H19 imprinting center (IC1) leading to H19 inactivation
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and IGF2 activation is found in 5%–10% of BWS patients and in
>25% of patients with Wilms tumor, hepatoblastoma, and rhab-
domyosarcoma (Choufani et al., 2010). Although the H19-IGF2
imprinting mechanism has been well documented and serves
as a paradigm for the study of epigenetic regulation, the func-
tions of H19 in biological and pathological molecular regulatory
processes remain nebulous. Recently, Varrault and colleagues
meta-analyzed the set of strongly correlated genes in microarray
data sets to infer the ‘‘Imprinted Gene Network’’ (IGN), of
which H19 is a member. This IGN may be part of the complex
regulatory system that induces rapid but controlled growth dur-
ing development (Varrault et al., 2006). H19 has been suggested
to regulate embryonic growth and differentiation by controlling
the expression of IGF2 and several other interconnected im-
printed genes; thus, fine-tuning equilibrium of growth activation
and repression (Gabory et al., 2009). These findings suggest
that H19 may execute its biological functions through the IGN.
Modeling human genetic diseases has been facilitated by
induced pluripotent stem cell (iPSC) methodologies (Takahashi
et al., 2007; Takahashi and Yamanaka, 2006; Yu et al., 2007).
Although iPSCs are widely utilized in the study of various genetic
diseases with either Mendelian or complex inheritance, their
application in cancer research has been much less extensively
explored. In the present study, we have modeled LFS-associ-
ated OS by using OBs derived from LFS patient-specific iPSCs
and were able to recapitulate disease characteristics. The LFS
iPSC-derived OBs displayed a clear OS gene expression signa-
ture whose particular transcriptional spectra strongly correlate
with clinical prognosis. By integrating global transcriptional and
computational analyses, we demonstrated that downregulation
of H19 and its associated IGN component DECORIN (DCN)
is responsible for LFS-associated OS development. Restoring
H19 expression facilitates OB differentiation and inhibits tumor-
igenesis. Downregulation of DCN impairs H19-mediated osteo-
genic differentiation and tumor suppression. In summary, our
results suggest that p53 mutation-mediated H19 and IGN inacti-
vation may contribute to OS development in LFS patients and
that induction of H19 expression may have important implica-
tions for the future treatment or prevention of LFS-associated
OS and/or OS with somatically acquired p53 mutations.
RESULTS
Generation and Characterization of LFS iPSCs
To elucidate how p53mutation results in tumor development, we
generated iPSCs from patient fibroblasts obtained from a LFS
family representing three LFS patients and two unaffected indi-
viduals (Figure S1A). The three patients have a heterozygous
c.734G>A mutation that causes a G245Dmissense substitution.
This site is one of the hot-spot p53 mutations in both LFS pa-
tients and somatic tumors (Varley, 2003). These patients present
with a broad spectrum of tumors, including OS, neurilemmoma
and astrocytoma (Figure S1A). The fibroblast samples displayed
a normal karyotype under low passage (Mirzayans et al., 2010).
Genome sequencing further confirmed heterozygous G245D
mutations in LFS fibroblasts (Figure S1B). Using non-integrating
Sendai virus (SeV)-based delivery of the four Yamanaka reprog-
ramming factors, OCT4, SOX2, KLF4, and c-MYC (Fusaki et al.,
2009; Takahashi et al., 2007), we established a number of iPSC
clones from the affected and unaffected family members. These
iPSC clones all demonstrate hESC morphology and express
pluripotency factors (NANOG, SOX2 and OCT4) and surface
markers (TRA-1-81 and SSEA4) and alkaline phosphatase (Fig-
ure 1A). The lines also show expression of pluripotency markers
at levels comparable to H9 and HES2 hESCs by quantitative (q)
RT-PCR and have a more open and demethylated OCT4 pro-
moter than the original fibroblasts (Figures 1B and 1C). We veri-
fied loss of SeV and exogenous OCT4, SOX2, KLF4, and c-MYC
transgenes (Figures S1C and S1D), demonstrating that these
iPSCs are zero-genetic footprint. Importantly, the iPSC lines
were karyotypically normal (Figure S1E) and demonstrated the
capacity to differentiate into all three germ layers in vitro (data
not shown) and in teratomas (Figure 1D). All characterizations
of wild-type (WT) and LFS iPSCs are summarized in Table S1.
Together, these data indicate that somatic cells from LFS pa-
tients can be properly reprogrammed, maintain a pluripotent
state and can be effectively differentiated.
Impairment of p53 Function in LFS iPSC-Derived
Mesenchymal Stem Cells
Asmentioned previously, OS, notably featuring defective OB dif-
ferentiation, is one of the major cancers affecting this LFS family.
Therefore, we applied our iPSC model to study how mutant p53
interferes with OB differentiation and to investigate themolecular
alterations caused by p53 mutation in OS development. Human
OBs can be induced from hESC-derived multipotent mesen-
chymal stem cells (MSCs) that can give rise to bone, cartilage,
muscle, and adipose tissues. We first differentiated WT and
LFS iPSCs to MSCs by treating them with FGF2 and PDGF-AB
and sorting CD105+/CD24 cells (Figure S2A). These cells also
expressed the MSC surface markers CD44, CD73, CD105, and
CD166, and the MSC-related transcription factor SNAI1 as well
as VIM (Figures 2A and S2B). The cells could be maintained for
2 months without loss of their MSC characteristics (Figure S2C)
(Lian et al., 2007). In comparison with WT MSCs, LFS MSCs
showed no mRNA expression differences of p53, MSC-associ-
ated transcription factors, and osteoblastic-associated factors
(Figures 2B, right, S2D and S2E). Nevertheless, LFS MSCs
showed lower mRNA expression levels of p53 targets p21 and
MDM2 (Figure 2B, left and middle). Compared with p53(WT),
p53(G245D) showed reduced binding to the p21 and MDM2
promoters by chromatin-immunoprecipitation (ChIP)-PCR anal-
ysis (Figure 2C), consistent with impaired transcriptional activity
(Figure 2B). UponMDM2 inhibitor Nutlin-3 treatment, expression
of numerous p53 target genes (p21, MDM2, SFN, NOXA, FAS,
TNFRSF10B, and GADD45A) were upregulated in WT MSCs,
but this effect was blunted in LFS MSCs (Figure 2D). All charac-
teristics ofWT andLFSMSCs are summarized in Table S1. These
studies demonstrate that LFSMSCsnot onlymaintainMSCchar-
acteristics identical toWTMSCs but also retain the defective p53
function of the parental fibroblasts (Barley et al., 1998).
Recapitulating OS Characteristics in LFS
MSC-Derived OBs
Since it was previously suggested that impairment of p53 func-
tion leads to OS (Walkley et al., 2008) and clinical OS samples
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Figure 1. LFS iPSCs Are Pluripotent
(A) SeV-4F (OCT4, SOX2, KLF4 and c-MYC) reprogrammed LFS and wild-type (WT) iPSCs derived from the same family express hESC pluripotency factors,
hESC surface markers, and AP activity.
(B) qRT-PCR assay for expression of endogenous human NANOG, SOX2, OCT4, DPPA4, REX1, and TERT in iPSCs and parental fibroblasts. PCR reactions are
normalized to GAPDH and plotted relative to expression levels in human H9 ESCs. Error bars indicate ± SEM of triplicates.
(C) Bisulfite sequencing analysis of the OCT4 promoter showing CpG hypomethylation in WT and LFS iPSCs relative to the parental fibroblasts. The cell line and
percentage of CpG methylation are indicated to the left of each cluster. Closed circle, methylated CpG; open circle, unmethylated CpG.
(D) In vivo teratoma formation assay demonstrates LFS iPSC capacity to differentiate into the three germ layers. H&E-stained teratomas containing embryonic
tissues all three germ layers, including enamel epithelium (endoderm); neural tube epithelium (ectoderm); cartilage corpuscle (mesoderm). Scale bar, 100 mm.
See also Figure S1 and Table S1.
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Figure 2. Defective p53 Activity in LFS MSCs
(A) Surface antigen profiling of LFS MSCs by flow cytometry demonstrating the CD24, CD105+, CD73+ and CD44+ fractions in differentiated MSCs.
(B) qRT-PCR analysis for expression of p53 and its downstream target genes, p21, and MDM2, in theWTMSC group (11 lines) and the LFSMSC group (13 lines).
The p53 mRNA levels do not show a significant difference between WT and LFS MSCs, while levels of p21 and MDM2 are significantly lower in LFS MSCs.
(C) ChIP-PCR demonstrating lower p53 binding affinity to p21 andMDM2 promoter region in LFSMSCs. IgG ChIP is a negative control. Error bars indicate ± SEM
of triplicates.
(D) qRT-PCR for expression of p53 and its target genes after treatment of LFS andWTMSCswith theMDM2 inhibitor Nutlin-3 for 6 hr. Upregulation of themajority
of p53 target genes is impaired in LFS MSCs in comparison with WT MSCs despite similar p53 expression in both MSC groups.
qRT-PCR data are represented as mean ± SEM; n = 3. See also Figure S2 and Table S1.
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Figure 3. LFS OBs Show Differentiation Defects and Oncogenic Properties
(A and B) Both AP (A) and alizarin red S (B) staining reveal the attenuation of OB differentiation in LFS OBs.
(C and D) Expression of OB lineage markers (C) and transcriptional regulators (D) during the OB differentiation time course.
(legend continued on next page)
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are largely composed of poorly differentiated or undifferentiated
OBs (Tang et al., 2008), we asked if dysregulation of p53 sig-
naling is responsible for the observed differentiation defects.
LFSMSCswere induced to theOB lineage and the differentiation
process was monitored over time. Several p53 targets were
gradually induced in WT but not LFS OBs during differentiation
(Figure S3A). Consistently, ChIP-PCR showed significantly
reduced p53 binding to the p21 and MDM2 promoters in LFS
OBs (Figure S3B). The decrease in p53 transcriptional activity
in late stage osteogenic differentiation (day 17) was confirmed
by a p53 reporter assay (Figure S3C). These findings suggest
that p53 signaling is active in WT OBs but impaired in LFS
OBs. AP staining for detecting bone-associated ALPL enzyme
activity (Figure 3A) and alizarin red S staining reflective of mineral
deposition by functional OBs (Figure 3B) showed slower differ-
entiation in LFS MSCs. Mineral precipitations were observed
on the surface of Petri dishes inWTbut not LFSOBs (Figure S3D).
Consistently, in comparison with WT OBs, LFS OBs showed
lower expression of COL1A1 and ALPL (pre-OB markers),
BGLAP/Osteocalcin, and PTH1R (mature OB markers), as well
as FGF23 and MEPE (osteocyte markers) during osteogenesis
(Figures 3C). Immunostaining confirmed that LFS OBs ex-
pressed lower BGLAP than WT OBs did (Figure S3E). Because
osteogenic differentiation is controlled by several core trans-
criptional/epigenetic regulators, we monitored their expression
levels during OB differentiation from LFS MSCs. Indeed, we
found impaired upregulation of ZNF521 and ZEB1 (Figure 3D),
indicating a defect in the normal OB gene regulatory network.
Knockdown of p53 resulted in upregulation of osteogenic mar-
kers in LFS OBs and eliminated the osteogenic differentiation
defect (Figure S3F) indicating that p53(G245D) may exert gain-
of-function instead of loss-of-function effects in inhibiting osteo-
genic differentiation. Moreover, we noticed LFS OBs growing in
randomly oriented piled-up foci rather than the two-dimensional
monolayers of flattened cells (Figure S3G), a generally regarded
manifestation of a transformed phenotype and an initiating
step in tumorigenesis. To further investigate whether LFS OBs
are able to recapitulate tumorigenic potential, we performed
in vitro anchorage-independent growth (AIG) assays and in vivo
xenografts. AIG assays showed clonal growth in soft agar by
many LFS OBs (6 out of 9) but not in WT OBs, undifferentiated
LFS or WT MSCs (Figure 3E). Performing xenografts in nude
mice, we found tumorigenic ability in LFS OBs but not WT OBs
(Figure 3F, right). The tumors demonstrated immature OB char-
acteristics including AP activity, collagen matrix deposition but
not mineralization (Figure 3F, left). The lack of in vitro and in vivo
tumorigenic ability in LFS MSCs implies that OS may originate
from immature or poorly differentiated OBs rather than MSCs
(Figures 3E and 3F). To examine whether LFS OBs are able to
gain malignancy during tumor progression, we performed serial
transplantation using an in ovo chick embryo chorioallantoic
membrane (CAM) model. As shown in Figure S3H, the tumor
sizes of LFS OBs increased in the second transplantation in
comparison with the first transplantation. These results imply
that similar to OS cells, LFSOBs contain a population of potential
tumor-initiating cells (TICs) and these cells are enriched during in
ovo primary transplantation and fuel secondary tumor growth.
Interestingly, no additional increases in malignant tumor growth
were seen following a tertiary transplantation. The persistence of
a WT p53 allele during serial CAM transplantations (Figure S3I)
provides a possible explanation for why there is no further gain
of tumor growth in the tertiary transplantation. Taken together,
these findings demonstrate that OS-related phenotypes (defec-
tive OB differentiation and tumorigenic ability) can be recapitu-
lated in LFS iPSC-derived OBs.
OS Spectrum Is Represented in LFS OBs
In order to gain insights into LFS-associated osteogenic defects
and tumorigenesis, the global transcriptome was investigated
by mRNA-seq during OB differentiation time courses (Table
S2). Expression profiles of LFS and WT time course samples
analyzed by Spearman’s rank correlation demonstrated that
gene expression profiles of LFS samples clustered together
but were distinct from WT samples (Figure 4A). The non-nega-
tive matrix factorization (NMF) method for extracting relevant
biological correlations based on gene expression data showed
that at day 0 LFS and WT MSCs clustered together, while at
days 7, 14, 17 differentiating LFS OBs are distinct from their
WT counterparts (Figure 4B). These results suggest that WT
and LFS MSC gene expression profiles are initially similar but
diverge during subsequent OB differentiation. Alignment of
reads at individual gene loci and quantification by fragments
per kilobase of exon per million fragments mapped (FPKM)
values confirmed the gradual increase of OB marker ALPL and
skeletal development regulators HOXA10, IGF2, and CLEC3B
in WT but not in LFS-derived cells (Figure S4A). Gene Ontology
(GO) analyses using Network2Canvas further revealed that
OB differentiation in WT MSCs (day 17 versus day 0) affects bio-
logical process genes mainly involved in skeletal system devel-
opment and cell motility, whereas genes upregulated in LFS
MSCs are primarily associated with an inflammatory response
(Figure 4C, upper and middle). Expression levels of several skel-
etal system development-related genes were greatly increased
during the WT osteogenesis time course but not in the LFS sam-
ples (Figure 4C, bottom). Moreover, expression levels of genes
involved in positive regulation of cell differentiation and negative
regulation of cell proliferation were significantly increased in WT
OBs. In contrast, genes involved in positive regulation of cell
cycle and mitosis were enriched in LFS OBs (Figure 4C, upper
and middle). Using the Mouse Gene Atlas database, genes
(E) In vitro AIG assay for tumorigenicity demonstrates colony numbers found in LFS OBs but not in WT OBs. Positive colonies after 1 month growth of differ-
entiated OBs in either MSC or OB differentiation media are those larger than 50 mm (scale bar, 50 mm).
(F) Tumor xenograft experiments by subcutaneous injection in NU/NU mice demonstrate that LFS OBs but not MSCs recapture in vivo tumorigenic ability. The
LFS2-B OB-derived tumors were examined by H&E, AP, picrosirius red, and von Kossa stains to examine morphology, bone-associated AP expression, collagen
production, and mineral deposits, respectively. Error bars represent ± SEM. Scale bar, 1 cm.
(C–E) Error bars represent ± SEM; n = 3.
See also Figure S3 and Table S1.
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upregulated at day 17 in WT OBs were more similar to the later-
stage differentiated mouse OB gene profiles than were LFS OBs
(Figure S4B). Further analyses of day 17 WT and LFS OB gene
expression revealed that the expression pattern in WT OBs is
similar to that of mouse OBs at day 21. In contrast, the gene
expression pattern of LFS OBs is closest to that of mouse
OBs at day 5 (Figure S4C). Consistent with our qRT-PCR ana-
lyses of p53 target gene expression (Figure S3A), gene set
enrichment analysis (GSEA) confirmed that many known and
predicted targets enriched in WT OBs relative to LFS OBs are
found disproportionately in the set of significantly (>3-fold) upre-
gulated genes in p53 transduced OS cells (Figure S4D). This
supports the dysregulation of p53 function that occurs during
LFS OB differentiation.
We next asked if the gene expression in LFS OBs is consistent
with an oncogenic signature derived from OS cell lines. We iden-
tified both OB and OS signature genes by using GenePattern to
compare the gene expression profiles between OB cells and OS
lines (GSE39262). We then applied GSEA to compare enriched
expressed genes betweenWT and LFSOBs against these signa-
tures. As shown in Figure 4D, OS-associated genes are specif-
ically enriched in LFS OBs; in contrast, OB-associated genes
are specifically enriched in WT OBs. This finding strongly sug-
gests that by the time of their generation, LFS OBs have already
acquired OS characteristics. Furthermore, to determine whether
the gene expression profiles of LFS OBs can potentially have
prognostic value as measured by patient survival and tumor
recurrence, we performed Kaplan-Meier analyses restricted to
two separate subsets of patients, those who had or did not
have an enriched LFS iPSC-derived OB gene expression signa-
ture as defined by enriched genes in LFS OBs versus WT OBs at
day 17. We found that the enriched LFS OB-associated gene
signature was significantly correlated with more rapid tumor
recurrence and poorer survival (p = 0.004 and p = 0.009, respec-
tively) (Figure 4E). In summary, our LFS iPSC model not only re-
captures the OS signature but can also predict clinical outcomes
in patients.
Cytogenetic analyses of human OS have revealed numerous
genomic alterations and rearrangements (Batanian et al., 2002;
Bridge et al., 1993) that have been consistently replicated in a
murine p53 conditional knockout OS model (Walkley et al.,
2008). Since genomic alterations are common during cancer
progression, it has been challenging to factor out their effects
when attempting to interrogate the roles of tumor suppressor
genes or oncogenes in tumor progression. To investigate if
our LFS OBs provide a unique model to study early stages of
tumor progression, we applied in silico cytogenetic region
enrichment analysis (CREA) to our LFS OB samples to identify
the potential presence of rearranged regions commonly found
in human OS. The LFS OBs were compared with the gene
expression signature of WT OBs at day 17 of OB differentiation,
while the synovial sarcoma (SS) was compared with normal
muscle. As expected, OS cell lines showed significant enrich-
ment at 10 of the 18 regions with known cytogenetic alterations
in OS. In contrast, human SS were generally not associated with
any alterations in these regions (Figure 4F), suggesting that
these chromosomal regions are a specific feature of OS rather
than a common feature of other cancers. Notably, in compari-
son with WT OBs, both LFS OBs and tumors showed negligible
enrichment in these regions (1 and 2 out of 18 regions, respec-
tively), implying that chromosomal rearrangements barely occur
in these LFS OB-derived tumors (Figure 4F). These results
demonstrate that LFS iPSC-derived OBs can serve as a useful
system to study the early stages of OS progression caused
solely by p53 mutation without interference by secondary
genomic alterations.
Impaired H19 Expression in LFS-Associated OS
Among 421 differentially expressed genes identified in compar-
isons between WT and LFS OBs, H19, highly expressed in OBs
but not in bone marrow or osteoclasts (Figure S5A), warranted
further in-depth analyses. Alignment and quantification of reads
at the H19 locus and qRT-PCR showed H19 upregulation in WT
but not LFS OBs during osteogenesis (Figures 5A and 5B). The
low expression of H19 in LFS OBs was further confirmed in
multiple LFS iPSC-derived OBs (Figure 5C). In comparison with
bone/OB tissues and p53 WT cells, H19 expression is signifi-
cantly decreased in OS and p53 mutant cells, respectively
(Figures 5D and 5E). These findings suggested that H19 dysre-
gulation is a common phenomenon in OS and is correlated
with p53 status. RNAi-mediated knockdown of H19 in WT OBs
led to decreased expression of osteogenic factors ZEB1 and
ZNF521, pre-osteoblastic makers ALPL and COL1A1 as well
as AP activity (Figure 5F). Supporting the positive regulatory
role of H19 in osteogenesis, ectopic expression of H19 in LFS
MSCs resulted in increasing osteogenic marker expression
and reactivation of OBswith consequent mineral deposition (Fig-
ure 5G). Moreover, AIG and oncosphere assays demonstrated
that in vitro tumorigenic activities of LFS OBs and OS TICs
were suppressed by re-expressing H19 (Figures 5H and 5I). In
LFS OBs assayed in ovo with the CAM assay and in vivo by
themouse tumor xenograft model, restoration of H19 expression
not only reduced the incidence of tumor development but also
decreased tumor size (Figures 5J and 5K). To further investigate
if restoration of H19 has any therapeutic potential for OS treat-
ment, H19 was transduced into OS cell lines, OSA and HOS.
As shown in Figure S5B, H19 reduced the incidence of OS tumor
development as well as tumor size, suggesting H19 as a thera-
peutic target. In comparison with the original OSA tumor, the
H19-transduced OSA tumor demonstrated poorly differentiated
osteoblastic characteristics including positive AP activity and
collagen matrix deposition but not mineralization, implying that
(C) GO biological processes associated with upregulated genes in WT and LFS OBs at day 17. FPKM values of skeletal system developmental genes are plotted
as a heat map demonstrating their upregulation during WT but not LFS-derived osteogenic differentiation.
(D) GSEA indicates that OS-associated genes are enriched in LFS OBs while normal OB-associated genes are enriched in WT OBs.
(E) OS patients with the LFS OB signature show shorter tumor recurrence and poorer survival.
(F) CREA analysis reveals chromosomal integrity of LFS OBs and tumors engrafted in nude mice.
See also Figure S4 and Tables S2 and S6.
Cell 161, 240–254, April 9, 2015 ª2015 Elsevier Inc. 247
H1
9
m
RN
A
re
ss
io
n
120
180
WT1-A
LFS1-A
LFS2-B
W
T1
-A
day 0
day 7
day 14
H19
74
2126
GBA
r
Alizarin Red S
15
18
LFS1-A_Vector
LFS1 A H19
Mature OB OC
on
250
240
day 17 OBs
*
Re
la
v
e
Ex
pr
day
0
60
0 5 10 15 20
day 17
day 0
day 7
day 14LF
S1
-A
3
40
104
96
3012
C
Ve
ct
o
H1
9
3
6
9
12
- _
LFS2-A_Vector
LFS2-A_H19
LFS2-B_Vector
LFS2-B_H19
Re
la
v
e
m
RN
A
Ex
pr
es
si
0
50
100
150
Re
la
v
e
H1
9
m
RN
A
Ex
pr
es
sio
n
day 17 OBs
day 17
day 0
day 7
day 14
day 17
LF
S2
-B
2
5
30
55
er
s
Vector H19IH
0
H19 PTH1R BGLAP MEPE FGF23
5
LF
S2
-B
O
Bs
8
10
Vector
H19
day 17 OBs
ED
6000
8000
10000
Ex
pr
es
sio
n
6000
8000
10000
Ex
pr
es
sio
n
WT LFS
Co
lo
ny
N
um
b e
Sp
he
re
N
um
be
rs
0
1
2
3
4
Vector
H19
0
2
4
6
******
day 17 OBs
shH19 1 shH19 3Ctrl
WT Mutant
2000
4000
p53
Status
H1
9
m
RN
A
E
Bone/OBs OS
2000
4000
H1
9
m
RN
A
E
J **LFS2-B_Vector
LFS2-B LFS2-DLFS1-A LFS2-B LFS3-A LFS3-C
s(
X1
05
)
15
10
**
_ _
W
T1
-A
1.5
Pre-OB Mature OB OCTF
day 17 WT1 A OBs
F
LFS2-B_H19
**
Vector H19
Ce
ll
N
um
be
r s
5
0
Vector H19
LFS1-A OBs LFS2-B OBsday 17
0 5
0.75
1
1.25
Ctrl
shH19_1
ShH19_3
la
v
e
m
RN
A
Ex
pr
es
sio
n
- K
m
or
W
ei
gh
t(
m
g)
50
40
30
20
0
0.25
.
H19 ZEB1 ZNF521 ALPL COL1A1 PTH1R BGLAP MEPE FGF23
Re Tu
m
10
0
LFS2-A LFS2-B LFS2-C LFS2-A LFS2-B LFS2-C
Vector H19
Tumor
Incidence 2/7 0/3 6/121/6 4/6 0/8
(legend on next page)
248 Cell 161, 240–254, April 9, 2015 ª2015 Elsevier Inc.
due to heterogeneity, a small portion of OSmay gain of the ability
to escape H19-induced OB differentiation and tumorigenic sup-
pression. In summary, these findings emphasize the essential
role of H19 in regulating osteogenesis and the potential of re-ex-
pressed H19 to rescue defective osteogenesis and suppress tu-
mor grow in both LFS iPSC-derived OBs and OS cell lines.
Since H19 expression has been shown to be suppressed by
p53 (Dugimont et al., 1998), we asked if this regulation was found
in LFS patients with mutant p53. Consistent with the previous
findings, activation of p53 by Nutlin-3 treatment decreased
H19 expression by 20%–39% (Figure S5C) and RNAi-mediated
p53 knockdown by two distinct RNAi molecules resulted in a
1.4- to 2.4-fold increase of H19 expression in WT MSCs (Fig-
ure S5D). In contrast, while suppression of H19 expression
was not detected in Nutlin-3 treated LFS MSCs (Figure S5C),
RNAi-mediated p53 knockdown led to a significant increase
in H19 expression (7.1- to 19.3-fold) (Figure S5D), strongly sug-
gesting that p53 mutants, at least p53(G245D), exert a gain-of-
function effect in repressing H19. In agreement with the hypoth-
esis that p53 does not bind the H19 promoter region and that
p53-mediated H19 repression occurs through other factors
(Dugimont et al., 1998), p53 ChIP showed no enrichment of
p53 binding in comparison with a control IgG pull-down (Fig-
ure S5E). To further explore whether other p53 mutants could
promote this regulation, we transfected multiple variants of
p53 into WT MSCs and examined their effects on H19 expres-
sion. As with p53(G245D), many p53 hotspot mutants (R175H,
G245S, G248W, and R280K) exhibited stronger inhibition of
H19 expression than didWTp53 (Figure S5F). This result demon-
strates not only that the suppression of H19 expression by p53
mutants is common in LFS-associated OS but also that this is
a general mechanism found in other LFS patients with distinct
p53 mutations. Since it was shown that the tumorigenic ability
of several p53 mutants is at least partially accounted for by their
interaction with and inhibition of p63 and/or p73 functions (Di
Como et al., 1999; Gaiddon et al., 2001), we investigated
whether p53(G245D) could inhibit H19 expression directly via
p63 and p73. Exogenous coimmunoprecipitation (coIP) showed
that p53(G245D) and p53(R175H) but not p53(WT) can interact
with p63 and p73 (Figure S5G). Depletion of p53(G245D) by
siRNA increased p21mini promoter activity in two LFS-derived
cells, LFS2-B (DWT)-1 and LFS2-B(DWT)-2 MSCs that lacked
a functional wild-type p53 allele due to insertion of a NeoR selec-
tion marker (D.-F. Lee and I.R. Lemischka, unpublished data).
Both p63 and p73 were able to activate the p21mini promoter
to a greater extent upon p53(G245D) knockdown (Figure S5H),
confirming the dominant-negative activity of p53(G245D) in
regulating p63 and p73 function. However, ectopic expression
of p63 and p73 does not alter H19 expression in WT MSCs
(Figure S5I). These findings suggest that although one of the
p53(G245D) gain-of-function effects in regulating LFS OS path-
ogenesis is through the suppression of normal p63/p73 function,
this regulation is not involved in H19 transcriptional regulation.
Recent studies have found that p53 status may affect DNA
methylation in theH19 genomic locus in a clone-specific manner
in iPSCs (Yi et al., 2012). To investigate whether impaired upre-
gulation of H19 in LFS OBs is caused by hypermethylation on
the H19 locus, differentiating LFS OBs were treated with the de-
methylating agent 50aza-deoxycytidine (Decitabine). As shown in
Figure S5J, H19 expression in LFS OBs was slightly increased
upon Decitabine treatment but remained significantly lower
than in WT OBs during OB differentiation, ruling out the possibil-
ity that lower H19 expression in LFS OBs is due to H19 locus
methylation. In fact, Decitabine-treated LFS OBs showed
impaired OB differentiation ability (Figure S5K) and slightly
increased in vitro tumorigenic potential (Figures S5L and S5M),
suggesting that the clinical application of demethylating re-
agents, at least Decitabine, in treating LFS patients with OS is
unlikely to provide much benefit.
Involvement of Human IGN in Osteogenesis and
Neurogenesis
Mouse H19 controls cell growth and development by regulating
the expression of several imprinted geneswithin the IGN (Gabory
et al., 2009). Interestingly, in comparison with other bone-asso-
ciated tissues, the expression of mouse imprinted genes is en-
riched in differentiated OBs and many of these are themselves
members of the IGN (9 out of 15; i.e., H19, Ndn, Igf2, Peg3,
Zac1, Sgce, Dlk1, Mest, and Cdkn1c) (Figure S6A). Additionally,
in comparison to normal mouse OBs, these imprinted genes,
including H19, are significantly downregulated in mouse OS
(Figure S6B). These results imply that the IGN may have a role
in osteogenesis and that its dysregulation may promote OS in
mice. We hypothesized that H19 suppresses LFS-associated
OS through the imprinted gene regulatory system. Since a hu-
man IGN was not yet established, we first searched for genes
frequently coexpressed with human imprinted genes and built
a human IGN from a database of 79 human tissues (178 arrays)
Figure 5. Involvement of H19 in LFS OB-Associated Defective OB Differentiation and Tumorigenesis
(A) Visualization of mRNA-seq short read mapping of H19 in UCSC Genome Browser.
(B) qRT-PCR shows impaired upregulated H19 in LFS during osteogenesis. Error bars indicate ± SEM; n = 3.
(C) Multiple LFS OBs have impaired upregulation of H19 during OB differentiation.
(D and E) H19 expression is notably decreased in OS and p53 mutant cells. The analyses were performed using microarray data from GEO dataset GSE36001.
(F) RNAi-mediated knockdowns of H19 inWTMSCs leads to decreased expression of osteogenic genes as well as AP activity. qRT-PCR data are represented as
mean ± SEM; n = 3.
(G) Ectopic expression of H19 in LFSMSCs increases osteogenic gene expression and facilitates OBmaturation. qRT-PCR data are represented asmean ±SEM;
n = 3. Scale bar, 100 mm.
(H and I) AIG (H) and oncosphere (I) assays show repressed in vitro tumorigenic ability of LFS OBs upon restoration of H19. Error bars are ± SEM; n = 3. Scale
bar, 100 mm.
(J) In ovo CAM assay indicates H19 suppresses tumorigenic ability of LFS OBs.
(K) In vivo tumor xenograft experiments indicating H19 suppression of tumorigenic ability of LFS OBs. Error bars represent ± SEM.
See also Figure S5.
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(human U133A/GNF1H Gene Atlas; GSE1133). Fifty-two im-
printed genes were extracted from total of 63 known and puta-
tive human imprinted genes (http://www.geneimprint.com/).
The main human IGN is composed of 16 imprinted genes and
divided into two sub-networks, the DCN and the NDN sub-IGN
(Figure 6A). The DCN sub-IGN includes four imprinted genes
(H19, DCN, IGF2 and CPA4) and the NDN sub-IGN contains 12
imprinted genes (NDN, PEG3, NNAT, MEG3, GNAS, MAGI2,
COPG2IT1, GRB10, DLGAP2, SNRPN, NTM and BLCAP). Tis-
sue-specific gene expression defines their unique biological
roles, and the enriched expressed genes, in general, have a
role in maintaining tissue or cell-specific functions. Imprinted
genes have been suggested to execute their functions through
modulating the expression of their coregulated genes. Accord-
ingly, we analyzed coregulated gene expression associated
with these 16 imprinted genes (Table S3) using the Mouse
Gene Atlas database. Interestingly, we found that the coregu-
lated genes associated with individual imprinted genes in the
DCN sub-IGN are primarily implicated in osteogenesis. In
contrast, the coregulated genes associated with the NDN sub-
IGN are mainly implicated in neurogenesis (Figure 6B). These
findings strongly indicate that although individual imprinted
genes participate in more diverse biological functions, the main
roles of the entire IGN are in osteogenesis and neurogenesis.
Gene expression analyses of 318 H19 coregulated genes sug-
gest that these may function in early OB differentiation as well
as lung, lactatingmammary gland, and ciliary body development
(Figure S6C). Interestingly, expression of these coregulated
genes is mainly enriched in early but not late OB differentiation.
This led us to suspect that H19 may function as an initiator of
osteogenesis and those downstream molecules, including core-
gulated imprinted genes, may function during later osteogenic
stages.
DCN functions downstream of H19 in LFS-Associated
OS Development
We next asked whether genes in the H19-associated IGN are
responsible for the observed H19-modulated OB differentiation
and oncogenic repression. We noticed that the imprinted gene
DCN, encoding a matrix proteoglycan, is directly linked to H19
in the IGN (Figure 6B) and that DCN-coregulated genes are rela-
tively overexpressed in OBs in a gradually increasing pattern
during osteogenesis (Figure 7A). Because we also realized that
the biological functions of DCN-coregulated genes are mainly
in cell adhesion and the cell matrix (Figure 7B), both of which
are known to regulate OB differentiation (Sosa-Garcı´a et al.,
2010), we pursued this candidate further. Alignment and quanti-
fication of reads at the DCN locus by FPKM values and qRT-PCR
showed that DCN is gradually upregulated in WT but not LFS
OBs during differentiation (Figures S7A and S7B). Decreased
DCN expression in LFS OBs was further confirmed in OBs
from multiple LFS iPSC lines (Figures S7C). DCN expression
was significantly decreased in OS and p53 mutant cells in com-
parisonwith bone/OB tissues and p53WT cells (Figures S7D and
S7E). RNAi-mediated knockdown of DCN led to decreased
expression of the osteogenic factor ZEB1, ALPL, and several
osteogenic differentiation-associated genes (Figure S7F), sup-
porting an essential role for DCN in normal osteogenesis.
Furthermore, knockdown of H19 downregulated DCN while
ectopic expression of H19 upregulated it in WT and LFS
Figure 6. A Network of Coregulated Human Imprinted Genes
(A) Genes linked to human imprinted genes, including H19, identified from a set of 79 human tissues. Fifty-two imprinted genes are extracted from total 63 known
and putative human imprinted genes. The main human IGN consists of 16 imprinted genes and contains two sub-networks.
(B) Network2Canvas analysis of these 16 imprinted coregulated genes by GO biological processes reveals that DCN-associated IGN primarily participates in
osteogenesis and NDN-associated IGN in neurogenesis.
See also Figure S6 and Table S3.
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MSCs, respectively (Figure S7G). In agreement with these re-
sults, DCN expression was directly correlated with H19 ex-
pression in both WT and LFS samples as well as in OS cell lines
(Figures S7H and S7I). In contrast, knockdown of DCN did not
alter H19 expression (Figure S7J). These findings demonstrate
that H19 functions as an upstream regulator of DCN expression.
To further elucidate whether DCN functions as a downstream
regulator involved in H19-mediated OB differentiation and tumor
suppression, we depleted DCN in LFS OBs expressing ectopic
H19 and found that H19-mediated upregulation of the pre-oste-
oblastic marker ALPL was abolished upon DCN knockdown
(Figure 7C) and that the in vitro and in ovo H19-mediated sup-
pression of LFS OB tumorigenesis was inhibited (Figures 7D
and 7E). These findings suggest that H19 regulation of osteogen-
esis and suppression of OS is, at least in part, mediated via DCN.
In comparison with MSCs, GSEA of DCN-coregulated genes re-
vealed their enrichment during OB differentiation (Figure 7F, left).
Additionally, in comparison with WT OBs and MSC/OB tissues,
DCN-coregulated genes were significantly decreased in LFS
OBs and OS (Figure 7F, right), implying that DCNmay negatively
regulate OS development. Supporting its tumor suppressor
function, ectopic expression of DCN reduced the incidence of
A
Uterus
Osteoblast Day5
Bladder
Umbilical Cord
Lung
Osteoblast Day14
Osteoblast Day21
p-value
7.44E-21
7.64E-19
7.47E-18
7.48E-18
5.87E-15
3.39E-10
1 09E 08Mesoderm Development
Immune System Process
Cell-Cell Adhesion
Cellular Process
Cell Communicaon
Signal Transducon
Cell Adhesion
GO Biological ProcessB
se
Ge
ne
At
la
s
DCN Coregulated Genes
0 10 20 30 40
Placenta
Ovary
Adipose White
p-value (-log10)
. -
1.75E-08
2.43E-08
6.10E-07
6.75E-07
0 50 100 150 200 250
Cell-Matrix Adhesion
Angiogenesis
System Development
Developmental Process
Expected
Observed
DCN
Coregulated Genes
Number of Genes in GO Category
M
ou
s
da
y
5
da
y
14
da
y
21
OBs
EDC 10
LFS1-A
8
LFS1-A
LFS2-B/H19_shCtrl
3 0
** **
LFS2-B/H19_shDCN-3
Re
la
v
e
AL
PL
m
RN
A
Ex
pr
es
sio
n
2
4
6
8
LFS2-B
LFS3-B
Co
lo
ny
N
um
be
rs
2
4
6
LFS2-A
LFS2-B
LFS3-B
Ce
ll
N
um
be
rs
(X
10
5 )
.
2.0
1.0
0
DCN Coregulated Genes
nt
Sc
or
e
(E
S)
NOM
F G
g)
800
**
OSA
15
*
HOS
H19 - + + +
- - 2 3shDCN
0
H19 - + +
- - +shDCN_3
0
LFS2-B_H19
shCtrl shDCN_3 shCtrl shDCN_3
LFS1-A_H19
DCN Coregulated Genes
tS
co
re
(E
S)
En
ric
hm
en
WT OB LFS OB
DCN Coregulated Genes
nt
Sc
or
e
(E
S)
NOM
Vector DCN
Tu
m
or
W
ei
gh
t(
m
g
600
400
200
0
Tumor Vector DCN
10
5
0
En
ric
hm
en
t
day 17 OBs day 0 MSCs
En
ric
hm
en
MSCs/OBs OS
Incidence 6/6 2/6 4/6 0/6
Figure 7. DCN Functions Downstream of H19 in LFS-Associated OS Development
(A) GO biological processes examined by Network2Canvas indicate DCN coregulated genes are significantly upregulated during osteogenesis.
(B) Panther analysis indicates DCN-coregulated genes are mainly involved in cell adhesion and cell matrix functions.
(C) H19-mediated upregulation of pre-osteoblastic marker ALPL is abolished upon DCN depletion. Error bars indicate ± SEM of triplicates.
(D and E) RNAi-mediated DCN knockdown impairs H19-mediated inhibition of LFS OB tumorigenic activity in vitro (D) and in ovo (E). Error bars indicate ± SEM,
n = 3 in (D).
(F) GSEA of DCN-correlated gene expression indicates expression of DCN network genes during OB differentiation that is impaired in LFS OBs and OS cells.
(G) DCN inhibits both OSA and HOS tumorigenesis. The sizes of HOS andOSA tumors were examined 1 and 2months after subcutaneous injection, respectively.
Error bars are ± SEM; n = 6.
See also Figure S7.
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OSA and HOS-initiated tumor development as well as tumor size
(Figure 7G). Taken together, these findings reveal that dysregu-
lation of the H19-DCN IGN is strongly linked to LFS-associated
osteogenic defects culminating in OS development.
DISCUSSION
In vitro modeling of human disease has been greatly facilitated
by iPSC methodologies (Takahashi et al., 2007; Takahashi and
Yamanaka, 2006; Yu et al., 2007). Characterized by their ability
to self-renew indefinitely and differentiate into all cell lineages
of an organism, iPSCs provide a powerful system for human dis-
easemodeling. The p53 tumor suppressor is considered a prom-
ising therapeutic target to treat tumors with p53 mutations or
deletions (Freed-Pastor and Prives, 2012). However, the lack of
a reliable model limits the development of useful approaches
to treat cancers caused by either genetic or somatic p53 muta-
tions. Instead of regular application of clinical patient samples,
cancer cell lines, and mouse models have been utilized to study
p53 function. Here, we demonstrate the possibility of using LFS
iPSCs to turn clinical samples into cell lines and models to study
the pathological mechanisms caused by mutations in p53. This
model system not only serves as an alternative tool to study
p53mutation-associated disorders but also provides substantial
benefits for studying the role of p53 in the early stages of tumor
development.
The Role of Mutant p53 in Osteogenesis and OS
A series of studies have demonstrated that the p53 tumor sup-
pressor promotes differentiation in a variety of cell types (Lee
et al., 2012a; Molchadsky et al., 2010). Since some types of can-
cer, such as OS, are considered undifferentiated, it is logical to
regard the cancer to be a defect in protective differentiation
that would normally suppress unchecked cell proliferation and
thus, prevent tumor development. However, recent in vivo
evidence from p53 knockout and conditional MDM2 deletion
mice, suggesting that wild-type p53 attenuates OB differentia-
tion and bone development (Lengner et al., 2006; Wang et al.,
2006), makes the situation far more complex. In our current
studies, we found that H19 promotes OB differentiation and
is repressed by p53; thus, providing a possible explanation
for how p53 can suppress OB differentiation. Strikingly, the
p53(G245D) mutant exerted a gain-of-function effect in re-
pressing H19 transcription (Figures S5D and S5F), indicating
that the defective OB differentiation in LFS OBs may result
from inhibition of H19-mediated osteogenesis. In contrast to
the p53(G245D) gain-of-function effect in downregulating H19
expression, this mutant exhibited a partial loss-of-function effect
in upregulating the majority of known p53 downstream targets
(e.g., MDM2, p21, and SFN). Advanced systems-level studies
to characterize p53(G245D) function by identifying genome-
wide differences between WT and mutant p53 will be needed
to elucidate the comprehensive mechanisms involved in LFS-
associated OS development.
Is H19 a Tumor Suppressor or an Oncogene?
It has been suggested that H19 may act as a tumor suppressor
(Hao et al., 1993; Yoshimizu et al., 2008). In contrast, several
in vitro culture experiments have suggested a controversial
oncogenic role for H19 (Lustig-Yariv et al., 1997; Verkerk et al.,
1997). This discrepancy could be explained by both differences
in the experimental systems and the complexity of H19 functions
in developmental and physiological processes. In our studies,
H19 is both significantly upregulated during osteogenesis and
commonly downregulated in OS, suggesting both differentia-
tion-promoting and tumor-suppressing roles. Moreover, ectopic
expression of H19 in LFSOBs restored normal osteogenic differ-
entiation. H19 acts not only by directly modulating downstream
targets as a lncRNA but also, indirectly controls an entire group
of genes via its associated IGN. Notably, many distinct cancers
are associated with dysregulation of imprinted genes (Joyce and
Schofield, 1998). Such dysregulation may disrupt the H19-asso-
ciated IGN and additional gene networks; thus, offering a
possible explanation for the distinct effects, variously as an
oncogene or a tumor suppressor observed after ectopic expres-
sion of H19. Moreover, it must also be acknowledged that the
H19 locus may play more complex roles than regulation of the
IGN, and these unidentified functions may also play roles in its
bivalent function in tumorigenesis both in different tissues and
at different tumor developmental stages.
LFS iPSCDiseaseModel: AnAlternative System to Study
the Early Stages of OS Development
One key feature of clinically apparent OS is its numerous
chromosomal alterations and rearrangements (Batanian et al.,
2002; Bridge et al., 1993). A high level of genomic instability, in
particular, chromosomal instability, is commonly found in OS.
Tumor suppressor genes are frequently lost and oncogenes
are duplicated. Because genomic instability is not only a conse-
quence of tumor progression but also an active driver of tumor
evolution, it creates a heterogeneous cell population and makes
it more difficult to understand the initial steps of tumorigenesis. In
comparison with normal differentiated OBs, human OS cell lines
and a conditional mouse OSmodel (Walkley et al., 2008) showed
strong enrichment of certain cytogenetic rearrangement regions.
Because human/mouse OS lines are only isolated after many
steps of tumor evolution, using these to study the initial
stage of OS tumorigenesis is challenging. In marked contrast,
LFS OBs and tumors showed a negligible degree of common
OS cytogenetic rearrangements in comparison with WT OBs
(Figure 4F), demonstrating the existence of a relatively intact
genome. This relatively undisturbed genome also helps to
explain the lower rate of and weak tumorigenicity of LFS OBs
in vitro and in vivo. Thus we anticipate that LFS iPSC-derived
OBs will be used in future studies focused on the role of mutant
p53 in early OS progression prior to development of broad
genomic alterations.
In summary, LFS iPSC-derived OBs not only provide a high-fi-
delity model system to elucidate the pathological mechanism of
p53 mutant-associated OS development but also document a
path for using LFS-associated gene expression patterns to pre-
dict clinical outcomes. More generally, iPSC approaches will
also facilitate the definition of inherited versus somatically ac-
quired causal components in many cancers. Further investiga-
tions to identify the regulatory mechanism of H19-DCN IGN
and to develop drugs to activate H19 and DCN may have
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powerful clinical implications for the treatment and/or prevention
of OS in patients with either inherited or somatically acquired p53
mutations.
EXPERIMENTAL PROCEDURES
Somatic Cell Programming with Non-Integrating SeV
The fibroblasts of three LFS patients and two unaffected relatives were
cultured and maintained in DMEM media supplemented 10% (vol/vol) Bench-
mark FBS (Gemini Bio-Product) and antibiotics. These fibroblasts were re-
programmed by transducing SeV expressing the four reprogramming factors
OCT4, SOX2, KLF4, and c-MYC (CytoTune reprogramming kit, Invitrogen) ac-
cording to manufacturer protocol. The reprogramming cells were maintained
in hESC media (DMEM/F12 [Cellgro, Mediatech] containing 20% [vol/vol]
KnockOut Serum Replacement [Invitrogen], L-glutamine, non-essential amino
acids, b-mercaptoethanol, antibiotics and bFGF). After 3–4 weeks post-induc-
tion, individual clones with hESC/iPSC morphology and positive for TRA-1-60
and TRA-1-81 live staining were picked, passaged on MEFs and examined for
loss of SeV by both staining with anti-SeV-specific antibody (PD029, MBL) and
by qRT-PCR measurement of expression of the exogenous four factors. The
specific qPCR primers targeting exogenous OCT4, SOX2, KLF4, and c-MYC
are listed in Table S4.
In Vitro Differentiation of iPSCs to MSCs
In vitro differentiation of WT and LFS iPSCs to MSCs was performed by a
well-defined MSC differentiation protocol described previously (Lian et al.,
2007). Briefly, iPSCs were seeded in gelatin-coated plates and cultured in
MSC-differentiation media (DMEM supplemented with 10% Knockout serum
replacement, 5 ng/ml FGF2 and 5 ng/ml PDGF-AB [PeproTech]) to induce
differentiation.When differentiated cells were confluent, cells were trypsinized,
split, and maintained. After 3 weeks of differentiation, the differentiated MSCs
were sorted as the CD105 (eBioscience)-positive and CD24 (BD PharMingen)-
negative cells by BD AriaII in the Mount Sinai Flow Cytometry Shared Facility
and expanded in MSC media (DMEM supplemented with 10% FBS). These
differentiated MSCs were further examined for expression of other MSC sur-
face markers CD44 (BD PharMingen), CD73 (BD PharMingen), and CD166
(BDPharMingen) aswell asMSC-associated factors SNAI andVIMby immuno-
staining with anti-SNAI1 (Santa Cruz) and anti-VIM (Millipore) antibodies.
In Vitro Osteogenic Differentiation of MSCs
LFS andWT iPSC-derived MSCs were plated in 12-well plate or 6-well plate at
a density of 13 104 cells or 23 104 cells per well, respectively, in osteogenic
differentiation medium (a-MEM supplemented with 10% FBS, 0.1 mM dexa-
methasone, 10 mM b-glycerol phosphate, and 200 mM ascorbic acid) (Barberi
et al., 2005). Cells were differentiated for specific time points as noted in the
main text before characterization.
In Vitro AIG and Oncosphere Assays
LFS and WT MSCs were cultured and passaged in 6-well plate at a density
of 2 3 104 cells per well. Cells were cultured in OB differentiation medium
for 7 days, split and 1 3 104 cells resuspended in OB differentiation medium
with 0.4%–0.5% LMP agarose. The cell suspensions were then plated in
12-well plates containing solidified 0.8% agarose in OB differentiation me-
dium. Cells were maintained in osteogenic differentiation medium for 1 month
with medium changes every 3 days. Colony (considered to have a diameterR
50 mm) were counted under a microscope. For the oncosphere assay, 23 104
7-day differentiated osteoblasts were washed by DPBS twice, resuspended
in oncosphere medium (a-MEM supplemented with 0.1 mM dexamethasone,
10 mM b-glycerol phosphate, 200 mM ascorbic acid, B27 supplement,
5 mg/ml Heparin, 20 ng/ml bFGF, and 20 ng/ml EGF), and seeded in ultra-
low attachment 6-well plates (3471, Corning). The number of oncospheres
(diameter R 50 mm) was calculated after 12 days.
Xenotransplantation
All animal procedures were performed in accordance with the Mount Sinai’s
Institutional Animal Care and Use Committee (IACUC). 23 106 Matrigel-mixed
differentiated osteoblasts, 2 3 106 Matrigel-mixed HOS (ATCC CRL-1543),
and 1 3 106 OSA (SJSA-1, ATCC CRL-2098) cells were injected subcutane-
ously into both right and left hind legs of 8-week-old immunocompromised
nude mice (Charles River Laboratories). Tumors were excised around 6–
10 weeks after injection. Tumors were weighed; fixed overnight in 10% neutral
buffer formalin; embedded in paraffin; sectioned; and stained with H&E, AP,
picrosirius red, and von Kossa stains to examine bone AP activity, AP expres-
sion, collagen matrix deposition,and mineralization, respectively, by HistoWiz.
Statistical Analyses
Results are expressed as the mean and error bars represent SEM. Difference
between two groupswere examined by two-tailed unpaired t test. *, p<0.05; **,
p<0.01; and ***, p<0.001.
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